Actively Recruiting
A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
Led by Eli Lilly and Company · Updated on 2026-03-02
787
Participants Needed
38
Research Sites
135 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a master protocol study to evaluate the long-term safety and efficacy of the drug pirtobrutinib in patients who have completed previous clinical studies involving this medication. This study includes participants with chronic lymphocytic leukemia or non-Hodgkin lymphoma and aims to monitor their health over an extended period. The master protocol organizes individual study-specific appendices (ISAs) representing participants from earlier originator studies. Participants continue to receive pirtobrutinib as they did in their original clinical study, with the drug administered orally. The study allows these individuals to keep taking the treatment or to continue with follow-up visits under this master protocol framework. The study is designed to gather safety and survival data over many years. During the study, participants will be closely monitored for any serious treatment-related side effects, with assessments focused on adverse events occurring from the first dose until shortly after the last dose or when starting a new anticancer therapy. Researchers will also track overall survival for up to 93 months. This long-term follow-up ensures comprehensive safety and health evaluations throughout the participant's involvement, which may last several years.
CONDITIONS
Brief Title
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Are participating in an eligible Lilly sponsored clinical study evaluating pirtobrutinib.
You will not qualify if you...
- Exclusion criteria are defined in each ISA.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - From first dose until discontinuation or start of new anticancer therapy
Participants receive pirtobrutinib orally as defined in the originator study.
Regular visits as per originator study schedule
Duration - Up to 30 days after last dose or start of new anticancer therapy, and overall survival monitored up to 93 months
Participants are monitored for safety and overall survival after treatment ends.
Visits for safety monitoring and survival follow-up as scheduled
Trial Site Locations
Total: 38 locations
1
Cancer Specialists, LLC
Jacksonville, Florida, United States, 32256
Not Yet Recruiting
2
Sylvester Comprehensive Cancer Center
Miami, Florida, United States, 33136-1002
Actively Recruiting
3
Florida Cancer Specialists
Sarasota, Florida, United States, 34232-6422
Actively Recruiting
4
The Emory Clinic
Atlanta, Georgia, United States, 30322-1013
Not Yet Recruiting
5
Northwestern University
Chicago, Illinois, United States, 60611-3013
Not Yet Recruiting
6
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
7
Mayo Clinic- Minnesota
Rochester, Minnesota, United States, 55905
Actively Recruiting
8
University Of Nebraska Medical Center
Omaha, Nebraska, United States, 69198
Actively Recruiting
9
Cayuga Cancer Center
Ithaca, New York, United States, 14850
Actively Recruiting
10
Northwell Health
Lake Success, New York, United States, 11042-1118
Actively Recruiting
11
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York, United States, 10065-6007
Actively Recruiting
12
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York, United States, 10065-6007
Not Yet Recruiting
13
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York, United States, 10065-6007
Not Yet Recruiting
14
Duke University Medical Center
Durham, North Carolina, United States, 27710-4000
Actively Recruiting
15
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210-1063
Actively Recruiting
16
University of Pennsylvania Hospital
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
17
Tennessee Oncology
Nashville, Tennessee, United States, 37203-2659
Actively Recruiting
18
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
19
Swedish Cancer Institute
Seattle, Washington, United States, 98104-3588
Actively Recruiting
20
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226-3548
Actively Recruiting
21
Flinders Medical Centre
Adelaide, Australia, 5042
Actively Recruiting
22
Peter MacCallum Cancer Centre
Melbourne, Australia, 3000
Actively Recruiting
23
Linear Clinical Research
Victoria, Australia, 3000
Actively Recruiting
24
CHU de Nantes - Hotel Dieu
Nantes, France, 44093
Actively Recruiting
25
IRCCS-AOU di Bologna-Policlinico S.Orsola-Malpighi
Bologna, Italy, 40138
Actively Recruiting
26
Ospedale San Raffaele
Milan, Italy, 20132
Actively Recruiting
27
Nagoya Medical Center
Aichi-Ken, Japan, 4600001
Actively Recruiting
28
National Cancer Center Hospital
Cho-ku, Japan, 104-0045
Actively Recruiting
29
National Hospital Organization Kyushu Cancer Center
Fukuoka, Japan, 811-1395
Actively Recruiting
30
Tokai University Hospital- Isehara Campus
Isehara, Japan, 259-1193
Actively Recruiting
31
Tohoku University Hospital
Miyagi-Ken, Japan, 9808574
Actively Recruiting
32
Hokkaido University Hospital
Sapporo, Japan, 060-8648
Actively Recruiting
33
Pratia MCM Krakow
Krakow, Poland, 30727
Actively Recruiting
34
Instytut Hermatologii I Transfuzjologii
Warsaw, Poland, 02776
Actively Recruiting
35
Seoul National University Hospital
Seoul, South Korea, 03080
Actively Recruiting
36
St James's University Hospital
Leeds, United Kingdom, LS9 7TF
Actively Recruiting
37
Churchill Hospital
Oxford, United Kingdom, OX3 7LE
Not Yet Recruiting
38
Derriford Hospital
Plymouth, United Kingdom, PL6 8DH
Actively Recruiting
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here